Piramal Pharma Raises Annual Growth Guidance
Chairperson Nandini Piramal said the company raised its annual growth guidance from the low-to-mid teens to the upper end of its stated range, expecting a significantly stronger second half.
Piramal Pharma Ltd has upped its annual guidance on the expectation that the second half of the year will be “significantly stronger”, said Chairperson Nandini Piramal.“We are confident to up our guidance from the low to mid-teens growth to the upper end of 19 per cent to 20 per cent growth. And gi…